Bacteriophages as antibacterial agents

Harefuah

Volumn 143, Issue 2, 2004, Pages 121-125

  Shasha, Shaul M ^a   Sharon, Nehama ^a   Inbar, Michael ^a  

^a WESTERN GALILEE HOSPITAL   (Israel)

Author keywords

Antibacterial agents; Antibiotic resistant bacteria; Bacteriophages; Multiple drugs resistant bacteria; Phage therapy

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; BACTERIOPHAGE; CLINICAL TRIAL; HUMAN; REVIEW; VIROLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOPHAGES; CLINICAL TRIALS; HUMANS;

EID: 3042704273     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (33)

1. Stone R, Stalin's forgotten cure. Science, 2002; 298: 728-731.
2. Sulakvelidze A, Alavidze & Morris JG, Minireview: bacteriophage therapy. Antimicrob Agents Chemother, 2001; 45: 649-659.
3. Twort FW, An investigation on the nature of ultramicroscopic viruses. Lancet, 1915; 2: 1241.
4. d'Herelle F, Sur un microbe unvisible antagoniste des bacilles dysenteruques. Compt Rend Acad Sci, (Paris) 1917; 165: 373-375.
5. Pirisi A, Phage therapy-advantages over antibiotics? Lancet, 2000; 356: 1418.
6. Chopra I, Hodgson J, Metcalf B & Poste G, Minireview: the search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother, 1997; 41: 497-503.
7. Das P, Bacteriophage therapy offers new hope for streptococal infection. Lancet, 2001; 357: 938.
8. Carlton MC, Phage therapy: past history and future prosects. Arch Immunol Therap Exp, 1999; 47: 267-274.
9. Alisky JK, Ichowski A, Rapoport A & Troitsky N, Bacteriophages show promise as antimicrobial agents. J Infect, 1998; 36: 5-15.
10. Barrow P & Soothill JS, Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol, 1977; 7: 268-271.
11. Levin BR & Bull JJ, Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat, 1966; 147: 881-898.
12. Hankin EH, L'action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann Inst Pasteur, 1896; 10: 511.
13. Van Helvoort T, Bacteriological and physiological research styles in the early controversy on the nature of the bacteriophage phenomenon. Med Hist, 1992; 3: 243-270.
14. Summers WC, Felix d'Herelle and the Origin of Molecular Biology. Yale University Press, New Haven, Conn, 1999.
15. Lwoff A, Lysogeny, Bacteriol Rev, 1953; 17: 269-337.
16. Ochs HD, Buckley RH, Kobayashi RH & al, Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood, 1992; 5: 1163-1171
17. Ochs HD, Nonoyama S, Zhu Q & al, Regulation of antibody responses: the role of complement and adhesion molecules. Clin Immunol Immunopathol, 1993; 67: S33-S40.
18. Bruynoghe R & Maisin J, Essais de therapeutique au moyen du bacteriophage. CR Soc Biol, 1921; 85: 1120-1121.
19. Eaton MD & Bayn-Jones S, Bacteriophage therapy. Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA, 1934; 23: 1769-1939.
20. Kruegerv A & Scribner EJ, Bacteriophage therapy II: the bacteriophage: its nature and its therapeutic use. JAMA, 1941; 19: 2160-2277.
21. Babalova EG, Katsitadze KT, Sakvarelidze LA & al, Preventive value of dried dysentery bacteriophage. ZH Mikrobiol Epidemiol Immunobiol, 1968; 2: 143-145.
22. Anpilov LI & Prokudin AA, Preventive effectiveness of dried polyvalent shigella bacteriophage in organized collective groups. Voenno Med Zh, 1984; 5: 39-40.
23. Slopek S, Weber-Dabrowska B, Dabrowski M & Kucharewicz- Krukowska, Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp, 1987; 35: 569-583.
24. Geier M, Frigg ME & Merril C, Fate of Bacteriophage lambda in non-immune germ free mice. Nature, 1973; 246: 221-222.
25. Merril CR, Biswas B, Carlton R & al, Long-Circulating bacteriophage as antibacterial agents. Proc Natl Acad, USA, 1996; 93: 3188-3192.
26. Wagner PL & Waldor MK, Minireview: bacteriophage control of bacterial virulence. Infect Immunology, 2002; 70: 398-399.
27. Kucharewicz-Krukowska A & Slopek S, Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exper, 1987; 35: 553-561.
28. Smith HW & Huggins RB, Successful treatment of experimental E. Coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol, 1982; 128: 307-318.
29. Smith HW & Huggins RB, Effectiveness of phages in treating experimental E. coli diarrhea in calves, piglets and lambs. J Gen Microbiol, 1983; 129: 2659-2675.
30. Smith HW & Huggins RB, The control of experimental E. coli diarrhea in calves by means ofbacteriophage. J Gen Microbiol, 1987; 133: 1111-1126.
31. Soothill JS, Treatment of experimental infection of mice with bacteriophage. J Med Bacteriol, 1992; 37: 258-261.
32. Soothill JS, Bacteriophage Prevents destruction of skin grafts by pseudomonas aeruginosa. Burns, 1994; 20: 209-211.
33. Biswas B, Adhya S, Washart P & al, Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant enterococcus faecium. Infection and Immunol, 2002; 70: 204-210.